News

APDA launches new awards program to sustain research

The American Parkinson Disease Association (APDA) has announced three recipients of its inaugural Bridge Funding Awards, a program designed to support promising Parkinson’s disease research when unexpected gaps in funding occur. The awards were open specifically to researchers APDA has funded within the…

Texas sets example with brain disease research investment: MJFF

Texas voters a a $3 billion state investment to support research into brain diseases such as Parkinson’s disease, a measure the Michael J. Fox Foundation for Parkinson’s Research (MJFF) called “a decisive step toward transforming the future of brain health and establishing itself as a model for other…

$5M grant funds new strategy to clear Parkinson’s proteins

A $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will help Booster Therapeutics develop therapeutics to improve the body’s ability to clear disease-causing proteins that drive Parkinson’s disease. The research grant will support studies into small-molecule therapeutics that activate the proteasome, a cellular…

Alector aims to seek FDA approval of Parkinson’s therapy in 2027

Alector said it is advancing the development of AL050, an enzyme replacement therapy for Parkinson’s disease, with an eye toward submitting an investigational new drug application to the U.S. Food and Drug Administration (FDA) in 2027. “We are well-resourced to advance our portfolio of innovative drug candidates for…

Trial testing light therapy device for Parkinson’s disease fully enrolled

Photopharmics has completed enrollment of a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, the company announced. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled 350 participants with Parkinson’s, surpassing the initial target enrollment of 300 patients. Topline results…